Your email has been successfully added to our mailing list.

×
0.0001003445161721 0.000167240860286833 0.000167240860286833 6.68963441147333E-05 0.00090310064554966 0.0014382713984681 0.000769307957320003 0.00127103053818107
Stock impact report

Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)

Agilent Technologies, Inc. (A)  More Company Research Source: Business Wire
Last agilent technologies, inc. earnings: 2/18 04:05 pm Check Earnings Report
US:NYSE Investor Relations: investor.agilent.com
PDF Companion diagnostic can help guide treatment decisions in cases of NSCLC SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the company’s PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union. PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) = 50% for treatment with Libtayo® (cemiplimab). This announcement underscores Agilent's continuing commitment to the development of IHC-based diagnostics for cancer therapy.Lung cancer is the leading cause of cancer death overall and the 2nd most commonly diagnosed cancer in Europe.1 NSCLC makes up approximately 85% of all lung cancer cases.2 In Europe, the average five-year survival rate for lung cancer is less than 20%.3 “This expanded indication for PD-L1 IHC 22C3 pharmDx will enable pathologists in Europe to identify patients wi [Read more]
Impact snapshot Event time: A
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
A alerts
from News Quantified
Opt-in for
A alerts

from News Quantified
Opt-in for
A alerts

from News Quantified